Index

• Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With A FGFR2 Fusion Or Rearrangement That Have Progressed After At Least One Prior Line Of Systemic Therapy
• F-Prime backed startup nabs another $50M in bid to scale up AI R&D software
• Loans Canada and Even Financial Announce Strategic Partnership to Help Canadian Borrowers
• Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors
• CENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development
• WellAir Announces Strategic Partnership with the Association for Professionals in Infection Control and Epidemiology (APIC)
• ShouTi Strengthens Board With Appointment of Daniel G. Welch as Chairman
• Ami Bavishi Joins Rallybio to Lead Investor Relations and Corporate Communications
• Global Health Technology Platform – Proximie – Announces Partnership With Vodafone Business to Increase Access to Surgical Healthcare and Training
• Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets
• Sana Biotechnology Obtains Exclusive License from National Institutes of Health for CD22 CAR Construct
• Parrot, a tool for digitizing Mexico’s restaurants, takes in $9.5M
• Pfizer re-ups gene editing interest with $300M Beam pact, $1.35B in biobucks
• Singular Genomics Partners with Lexogen to Enable RNA Library Prep for the G4 Sequencing Platform
• Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct
• Laekna Therapeutics and Innovent Biologics obtain IND approval for combination therapy in patients with specific types of solid tumors who have been refractory to treatment with PD-1/PD-L1 inhibitors
• RareCyte® Inc. reports significant 2021 growth of Precision Biology™ Services business and customer uptake of Orion™ Spatial Biology instruments and reagents
• Nomi Health Acquires Artemis Health to Accelerate Transformation of U.S. Healthcare with Actionable Insights
• Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation
• Innovusion Showcases Mass Production Ready Falcon and New LiDAR Robin at CES 2022
• Gene therapy biotech Affinia Therapeutics files for a $100 million IPO
• Even Financial Appoints Industry Veteran Andrew Naoum as Senior Vice President of Sales
• Odaseva’s Commitment to Enabling Business Agility with Data Management Leads to Record Year of Growth
• Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH
• Amgen, Owkin study shows cardiac-predicting AI outperforms traditional clinical methods
• Singular Genomics Launches the G4 Sequencing Platform
• BioMarin and Skyline Therapeutics Announce Strategic Collaboration to Develop Novel Gene Therapies for Cardiovascular Diseases
• MoneyLion to Acquire Even Financial, Expanding Distribution Network and Enhancing Consumers’ Financial Access and Decision Making
• Flywire Acquires WPM to Accelerate Expansion in the U.K. Market
• AvantStay, a platform for kitting out-and then renting out-high-end vacation rental homes, raises $160M
• Affinia Therapeutics Appoints Thomas Leggett as Chief Financial Officer
• Virtua Health Selects Kyruus’ Digital Platform to Simplify How Consumers Access Care Online
• Quartet Health Acquires InnovaTel Telepsychiatry, Making Shared Vision of Speed to Quality Mental Health Care for All a Reality
• Acacia Pharma Announces Successful Completion of BARHEMSYS® Post-approval Requirement Study in Patients with Severe Renal Impairment
• Adagene Presents Preclinical Data Showcasing Best-in-Class Profiles for ADG153, an Anti-CD47 SAFEbody® and ADG152, a CD20xCD3 Bispecific T-cell Engager POWERbody™
• Quartet picks up InnovaTel Telepsychiatry to expand its reach in the digital mental health market
• Beam Therapeutics Outlines Long-term Strategy for Base Editing Programs in Sickle Cell Disease and Provides Preclinical Data Updates at ASH
• Carrot Fertility Expands Executive Team, Hires Former Aetna Executive as Chief Commercial Officer
• 1upHealth Named as “Most Innovative Digital Health Startup” by CB Insights’ Digital Health 150
• Quartet Health snaps up fellow mental health company InnovaTel Telepsychiatry
• Proximie Partners with Jhpiego in New Initiative to Improve Obstetric Surgical Care
• Atlas, F-Prime launch K36 Therapeutics to advance oncology molecule for elusive epigenetic target
• NOCD Named to the 2021 CB Insights Digital Health 150 — List of Most Innovative Digital Health Startups
• HealthEdge Completes Acquisition of Wellframe
• Ochsner Health Makes Finding the Right Provider Easier with Solutions from Kyruus
• Stride partners with 100+ flexible work platforms and employers in support of “Gig Workers’ Week of Action” to boost health insurance enrollment before Dec. 15th deadline
• Nature Medicine Publishes Results from Two Registration Studies of AYVAKIT® (avapritinib) Showing Sustained Benefits in Patients with Advanced Systemic Mastocytosis
• CF Foundation Invests $3.5 Million in Pulmocide for Development of Novel Antifungal Treatment for Lung Transplant Recipients
• Even Financial Named to The 2021 Deloitte Technology Fast 500™
• Innovent and Lilly Announce Successful Expansion of Sintilimab in China National Reimbursement Drug List to Include Three Additional First-Line Indications
• Independence Health Group and Quartet Health Announce Strategic Partnership to Drive Speed to Mental Health Care
• Innovent and Lilly Announce Successful Expansion of Sintilimab in China National Reimbursement Drug List to Include Three Additional First-Line Indications
• Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results
• AviadoBio™ Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform
• Fiverr Teams Up With Stride Health to Help Fiverr Community Access Affordable Healthcare
• Rallybio Reports Positive Data in Its Clinical Program for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
• Surface Oncology Announces FDA Clearance of IND Application for GSK4381562, a Novel Antibody Targeting PVRIG
• Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type III
• Avivomed Raises $32 Million in Series A Financing
• Insilico Medicine Initiates First-in-Human Study of ISM001-055, a Novel Drug Discovered Using Insilico’s Proprietary End-to-end Artificial Intelligence Platform
• Turnstone Biologics Announces Research Collaboration with Moffitt Cancer Center to Advance Novel TIL Immunotherapies for Solid Tumor Indications
• Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination Therapy with Anti-PD-1 Antibody Pembrolizumab
• Verve Therapeutics Appoints Allison Dorval, Experienced Financial Executive, as Chief Financial Officer
• Ultragenyx Announces Additional Positive Multi-Year Durability Data from Phase 1/2 AAV Gene Therapy Studies
• Cloud R&D developer Benchling picks up second nine-figure venture capital haul this year
• Tempest Announces First Patient Dosed with TPST-1495 in Combination with Pembrolizumab
• OTA Insight books $80M for its hospitality business intelligence tools, used by 55K hotel properties globally
• Owkin becomes ‘unicorn’ with $180m investment from Sanofi and four new collaborative projects
• Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome
• WellAir Launches New Air Cleaning Device That Is 99.9% Effective Against Indoor Airborne Pathogens
• Cytek® Biosciences Marks Milestone Achievement with Shipment of 1000th Cell Analysis System
• BenchSci Named a Deloitte Technology Fast 50™ Company as Impact on Drug Discovery Grows
• Denali Therapeutics Announces Strategic Partner Takeda Exercises Option to Co-Develop and Co-Commercialize DNL593 (PTV:PGRN)
• Recurly to Exceed $10 Billion in Transaction Payment Volume as Pay-As-You-Go Subscription Models Accelerate
• iVest+ Announces Integration with Tradier to Serve Its Expanding Active Trader Community
• Embark sponsors The National Dog Show, in commitment to improving life and longevity of all dogs
• FDA Grants AppliedVR Approval for First Virtual Reality Therapeutic to Treat Chronic Low Back Pain
• Innovent Announces the Results of the Phase Ib Clinical Trial of IBI302, a First-in-class Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2021 American Academy of Ophthalmology
• Tempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach for Targeting the Prostaglandin Pathway in Cancer
• AppliedVR Raises $36 Million Series B To Scale Comprehensive Virtual Reality Platform For Healthcare
• Former ONC leader Rucker joins interoperability startup 1upHealth
• Online medical store PharmEasy targets $842 mln India IPO
• Singular Genomics Expands Early-Access Program for New DNA Sequencing Instrument
• Protenus Expands Executive Team With Addition of Experienced Health Tech Leader
• Notabene raises $10.2M to help crypto exchanges comply with new global regulations
• Centivo launches integrated virtual advanced primary care offering
• Innovent Publishes the Preclinical Results of IBI319 (Anti PD-1/CD137 Bispecific Antibody) in Nature Communications
• Avidity Announces First Person Dosed with an Antibody Oligonucleotide Conjugate (AOC™)
• Adagene Unveils Preclinical Data from Two Transformative Antibody Programs at Upcoming American Society of Hematology (ASH) Annual Meeting
• Notable, which makes RPA-based tools to speed up healthcare admin, raises $100M at a $600M valuation